Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules

Senescence Elicits Stemness: A Surprising Mechanism for Cancer Relapse

(2018) Zhixun Dou et al.   Cell Metabolism

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

(2018) Deng Pan et al.   SCIENCE

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

(2018) Diana Miao et al.   SCIENCE

Senescence-associated reprogramming promotes cancer stemness

(2017) Maja Milanovic et al.   NATURE

Synergistic gene expression during the acute phase response is characterized by transcription factor assisted loading

(2017) Ido Goldstein et al.   Nature Communications

Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy

(2017) Kai Shi et al.   Frontiers of Chemical Science and Engineering

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer

(2017) Isobel S. Okoye et al.   Frontiers in Immunology

Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities

(2016) S. Cousin et al.   CLINICAL CANCER RESEARCH

Immune suppressive mechanisms in the tumor microenvironment

(2016) David H Munn et al.   CURRENT OPINION IN IMMUNOLOGY

AS-IL6promotes glioma cell invasion by inducing H3K27Ac enrichment at theIL6promoter and activatingIL6transcription

(2016) Yu Wang et al.   FEBS LETTERS

Serine/Arginine-rich Splicing Factor 2 Modulates Herpes Simplex Virus Type 1 Replication via Regulating Viral Gene Transcriptional Activity and Pre-mRNA Splicing

(2016) Ziqiang Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

The epigenetic landscape of T cell exhaustion

(2016) D. R. Sen et al.   SCIENCE

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

(2016) K. E. Pauken et al.   SCIENCE

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

(2015) K Cao et al.   ONCOGENE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity

(2013) D. M. S. Hossain et al.   BLOOD

Histone modifications for human epigenome analysis

(2013) Hiroshi Kimura   JOURNAL OF HUMAN GENETICS

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

SC35 promotes splicing of the C5-V6-C6 isoform of CD44 pre-mRNA

(2013) TIING JEN LOH et al.   ONCOLOGY REPORTS

Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription

(2013) V. R. Moulton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis

(2012) H. Makishima et al.   BLOOD

Genome-wide analysis of STAT3 binding in vivo predicts effectors of the anti-inflammatory response in macrophages

(2012) A. P. Hutchins et al.   BLOOD

The Nuclear-Retained Noncoding RNA MALAT1 Regulates Alternative Splicing by Modulating SR Splicing Factor Phosphorylation

(2010) Vidisha Tripathi et al.   MOLECULAR CELL

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET

Loss of CTL Function among High-Avidity Tumor-Specific CD8+ T Cells following Tumor Infiltration

(2008) C. N. Janicki et al.   CANCER RESEARCH

E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35

(2008) G Merdzhanova et al.   CELL DEATH AND DIFFERENTIATION

A rapid micro chromatin immunoprecipitation assay (ChIP)

(2008) John Arne Dahl et al.   Nature Protocols

Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice

(2008) A. Bai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA